aibioaibio.space
Biotech data trackers
Running lists of biotech class actions, reverse splits and delistings, reverse mergers and the biggest share moves, built from fact-checked stories and free to cite.
Friday, October 23, 2026Biotech Investor Relations News
- Debt Financing Pelthos amends Horizon venture loan, funds Loans E to H and adds Loans I and J
- Debt Financing Repligen announces $1.0 billion private convertible notes transaction
- Company Updates PTC reports third-quarter 2026 revenue of $358 million and raises product guidance
- Company Updates Processa clears VT-7208 CSU IND and names a new executive chair
- Company Updates Kiora in-licenses late-stage KIO-401 for retinal artery occlusion
- Company Updates Azitra expands ATR-04 trial to rash from KRAS and MEK inhibitors
- Debt Financing FOXO to buy Ludwig Enterprises preferred stock with majority voting power
- Company Updates Dermata enrolls first participant in Tome Clearing Treatment trial
- Legal Alnylam details Texas patent suit, two Cipla patent cases and a U.S. Attorney subpoena
- Legal Viking and Ligand dispute VK2809 license termination in San Diego court
- Legal Viking's ITC trade secret ruling against Ascletis is on appeal at Federal Circuit
- Legal Court rules for Teva and Apotex in Vanda's HETLIOZ patent suits
- Legal Indivior discloses Suboxone dental injury MDL of about 22,098 plaintiffs; no bellwether before 2028
- Debt Financing Altimmune draws $10.0 million third tranche from Hercules loan facility
- Legal European patent court rules Enanta patent invalid in Paxlovid suit against Pfizer
- Financings INmune Bio raises $4.50 million in registered direct offering with warrants